Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6CH, genotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: The present invention relates to nucleic acid sequence which comprises the genome of an infectious GB virus B clone. The invention also relates to the use of the nucleic acid sequence of the infectious GB virus B clone to indirectly study the molecular properties of HCV, and in the production of HCV/GBV-B chimeras. The invention further relates to the use of the infectious nucleic acid sequence of GB virus B clone and the HCV/GBV-B chimeras in the development of vaccines and therapeutics for HCV.

Abstract: The present invention discloses nucleic acid sequence which encodes infectious hepatitis C virus of strain HC-J6CH, gentotype 2a, and the use of the sequence, and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Abstract: An amphipathic compound represented by any of the following Formulas: ##STR1## (R.sub.1 is a linear or branched, saturated hydrocarbon group having 6 to 48 carbon atoms, or a linear or branched, unsaturated hydrocarbon group containing 1 to 12 unsaturated double bond and having 6 to 48 carbon atoms; Y is NH, N--(CH.sub.2 --CH.dbd.CH.sub.2), or O; Q is --CH.sub.2 --C(R.sub.2).dbd.CH.sub.2 or --R.sub.4 --O--CO--C(R.sub.2).dbd.CH.sub.2 ; and M is alkali metal, an ammonium group, or --(CH.sub.2 CH.sub.2 O).sub.m H), a copolymer of the amphipatic compound with a copolymerizable ethylenically unsaturated compound and, a paper making additive containing a water soluble or dispersible high molecular compound as an active ingredient and processes for producing these high molecular compounds.

Abstract: Provided are an amphipathic compound represented by any of the following Formulas: ##STR1## (R.sub.1 is a linear or branched, saturated hydrocarbon group having 6 to 48 carbon atoms, or a linear or branched, unsaturated hydrocarbon group containing 1 to 12 unsaturated double bond and having 6 to 48 carbon atoms; Y is NH, N--(CH.sub.2 --CH.dbd.CH.sub.2), or O; Q is --CH.sub.2 --C(R.sub.2).dbd.CH.sub.2 or --R.sub.4 --O--CO--C(R.sub.2).dbd.CH.sub.2 ; and M is alkali metal, an ammonium group, or --(CH.sub.2 CH.sub.2 O).sub.m H), a copolymer of the amphipatic compound with a copolymerizable ethylenically unsaturated compound and, a paper making additive containing a water soluble or dispersible high molecular compound as an active ingredient and processes for producing these high molecular compounds.

Abstract: A method for inhibiting dopamine re-uptake and treating Parkinson's disease is disclosed comprising administering a compound represented by formula (1) or a physiologically acceptable salt thereof as the active ingredient: ##STR1## wherein R.sup.1 and R.sup.2 represent each hydrogen or halogen, R.sup.3 represents hydrogen, alkyl or acyl, R.sup.4 represents hydrogen, alkyl, acyl, alkylsulfonyl or optionally esterified carboxyl, Ar represents optionally substituted phenyl or nitrogenous monocyclic heteroaromatic group, m represents a number of 1 to 5, and n represents a number of 0 to 5.

Abstract: A diphenylpiperazine derivative represented by general formula (1), salt thereof, and drug for the circulatory organs containing the same as the active ingredient: ##STR1## wherein R.sup.1 and R.sup.2 may be the same or different from each other and each represents hydrogen, halogen, alkyl, alkoxy, nitro, amino, hydroxy, optionally esterified carboxyl or trifluoromethyl; R.sup.3 represents hydrogen, alkyl, aralkyl, acyl, nitro or optionally esterified carboxymethyl; Ar represents phenyl or naphthyl which may have one to three substituents such as halogen, alkyl, alkoxy, aryloxy, aralkyloxy, nitro, amino, cyano, acyl, hydroxy, optionally esterified carboxyl, substituted sulfonyl, aryl or trifluoromethyl; Z represents sulfur or -NR.sup.4 - wherein R.sup.4 represents hydrogen, alkyl, aralkyl, acyl, aryl, substituted sulfonyl or optionally esterified carboxyl; m represents a number of 1 to 5; and n represents a number of 0 to 5.